TLDR
- AbbVie rises as EU clears Skyrizi for pediatric psoriasis patients.
- Skyrizi approval expands AbbVie’s reach in Europe’s immunology market.
- EU backs Skyrizi use in children aged six and older with psoriasis.
- New syringe supports weight-based dosing for younger Skyrizi users.
- ABBV gains after pediatric approval strengthens its Skyrizi portfolio.
AbbVie shares rose 1.81% to $234.18 after European regulators expanded Skyrizi’s use for pediatric plaque psoriasis. The stock climbed steadily and remained near its intraday highs during late afternoon trading. The approval broadens AbbVie’s immunology reach and adds a younger patient group across European markets.
EU Approval Expands Skyrizi Access
The European Commission approved Skyrizi for children and adolescents aged six years and older. Eligible patients must have moderate-to-severe plaque psoriasis and qualify for systemic therapy. The decision gives physicians another treatment option for younger patients with more serious forms of the disease.
Regulators also approved a new 55-milligram pre-filled syringe for weight-based dosing. AbbVie developed the formulation for patients weighing less than 40 kilograms. Therefore, the product supports more precise treatment administration across different pediatric weight groups.
The approval extends Skyrizi’s European label beyond its established adult uses. Those indications include plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. AbbVie now strengthens the medicine’s position within its broad and established immunology portfolio.
Phase 3 Data Supports Regulatory Decision
AbbVie supported the application with results from the Phase 3 OptIMMize-1 pediatric psoriasis program. The program included separate study groups for adolescents and younger children. Researchers also used findings from the Phase 3 OptIMMize-2 open-label extension study.
Across the studies, 137 pediatric patients received treatment with Skyrizi. AbbVie reported a safety profile consistent with previous results from adults with moderate-to-severe plaque psoriasis. The company identified no new safety signals during the pediatric clinical program.
The studies also examined dosing and drug exposure across different age and weight groups. These findings helped regulators assess treatment use in children from six years onward.The evidence supported both the expanded indication and the new syringe formulation.
Pediatric Psoriasis Creates Broader Treatment Need
Psoriasis often begins before adulthood and can affect visible areas such as the face and scalp. Early symptoms may disrupt school attendance, social activity, and emotional well-being. Moderate-to-severe cases can also require stronger treatment beyond topical medicines.
AbbVie reported that nearly one-third of psoriasis patients develop symptoms before age 18. The company also said about 70% of pediatric patients rely only on topical therapies. That treatment pattern leaves fewer choices for children with more extensive or persistent disease.
Skyrizi blocks interleukin-23 by targeting its p19 subunit. That pathway plays a role in inflammatory conditions and supports the medicine’s existing approved uses. The latest authorization expands AbbVie’s pediatric footprint while supporting continued growth across its immunology business.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
